Angeles Secord, MD
Gynecologic Oncology · Durham, NCNPI 1073531083
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.1%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 37.2% of the total. Among gynecologic oncology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $742.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$45K
- GSK$20K
- Merck$9K
- Tesaro, Inc.$8K
- Daiichi Sankyo Inc.$6K
- Genmab U.S., Inc.$5K
- plus $28K from 17 others
Across 312 payments — averaging $14,432 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.1M
- GSK$700K
- Genentech, Inc.$552K
- Clovis Oncology, Inc.$331K
- AbbVie$230K
- Immunogen, Inc.$113K
- plus $438K from 10 others
What the payments were for
- Consulting fees$54,50945%
- Speaking & faculty fees$7,9807%
- Grants$45,00037%
- Travel & lodging$8,1817%
- Food & beverage$5,1974%
- Education$1260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $45,000 |
| GSK | 33 | $20,447 |
| Merck | 11 | $9,076 |
| Tesaro, Inc. | 13 | $7,818 |
| Daiichi Sankyo Inc. | 6 | $6,334 |
| Genmab U.S., Inc. | 4 | $4,800 |
| Clovis Oncology, Inc. | 15 | $4,506 |
| AbbVie | 16 | $4,100 |
| Seagen Inc. | 2 | $3,537 |
| Histosonics, Inc. | 2 | $3,143 |
| Eisai Inc. | 15 | $3,068 |
| Medtronic | 2 | $2,590 |
| AstraZeneca | 19 | $2,511 |
| Myriad Genetic Laboratories, Inc. | 1 | $1,500 |
| Corcept Therapeutics | 6 | $1,139 |
| Immunogen, Inc. | 4 | $305 |
| Astrazeneca UK Limited | 4 | $252 |
| Genentech USA, Inc. | 2 | $230 |
| Karyopharm Therapeutics Inc. | 2 | $227 |
| Pfizer | 1 | $135 |
| Roche Diagnostics Corporation | 2 | $135 |
| Johnson & Johnson | 1 | $80 |
| F. Hoffmann-la Roche AG | 1 | $60 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$120,992 in reported general payments places this provider in the 95th percentile of 52 gynecologic oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Durham
- William LoweryDurham$67K
- Andrew BerchuckDurham$12K
- Haley MossDurham$2K
- Laura HavrileskyDurham$29
- Lucybeth Nieves ArribaWilmington$251K
- Robert NaumannCharlotte$221K
- Erin CraneCharlotte$98K
- Michael SundborgSouthern Pines$85K
- Emma RossiGreensboro$62K
- Jubilee BrownCharlotte$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.